Anti-Cancer Drugs
Journal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | 2.0 | Q3 | 30.3% | 0.506 | Q3 | 61.3% |
| 2024 | 2.2 | Q3 | 41.1% | 0.532 | Q3 | 64.3% |
| 2023 | 1.8 | Q3 | 33.8% | 0.476 | Q3 | 63.2% |
| 2022 | 2.3 | Q3 | 38.5% | 0.471 | Q3 | 64.5% |
| 2021 | 2.4 | Q4 | 42.5% | 0.463 | Q3 | 64.7% |
| 2020 | — | — | 0.651 | Q2 | 74.2% | |
| 2019 | — | — | 0.636 | Q2 | 74.3% | |
| 2018 | — | — | 0.684 | Q2 | 74.4% | |
Impact history
Annual SJR and Impact Factor trend.
SJRIF
Journal record
eISSN
1473-5741
ISSN
0959-4973
country
UScoverage
1990-2026